Callisto has an experienced, well-respected management team, with hands-on experience in various facets of drug discovery and development at both large and small pharmaceutical companies.

Gary S. Jacob, Ph.D.

Chief Executive Officer and Chief Scientific Officer

Gary S. Jacob, Ph.D. has served as Chief Executive Officer and Chief Scientific Officer since May 2003, and Chairman of Synergy Pharmaceuticals Inc. since October 2003. Dr. Jacob formerly served as Chief Scientific Officer of Synergy Pharmaceuticals Inc. from 1999 to 2003. From 1990 to 1998, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of Glycobiology. From 1997 to 1998, Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, Monsanto. From 1990 to 1997, Dr. Jacob was Director of Glycobiology, G.D. Searle Pharmaceuticals Inc. From 1986 to 1990, Dr. Jacob was Manager of the G.D. Searle Glycobiology Group located at Oxford University, England. Dr. Jacob received his Ph.D. in biochemistry from the University of Wisconsin-Madison, and his Bachelor of Science degree (with honors) in chemistry from the University of Missouri – St. Louis.

Robert C. Shepard, M.D., F.A.C.P.

Chief Medical Officer

Robert C. Shepard, M.D., F.A.C.P. has been Callisto’s Chief Medical Officer since August 2006. Prior to Callisto, Dr. Shepard was Senior Director and Head of US Oncology at i3 Research, and has served as a Medical Director of Clinical Research and Development in oncology at AstraZeneca and as Medical Officer at the oncology branch of CBER at the FDA. His previous experience includes 15 years in clinical research at Harvard, Tufts, Johns Hopkins, and the University of Virginia where he was Principle Investigator for 29 oncology clinical trials and the PI for ECOG.

Arthur Sytkowski, M.D.

Clinical Trial Advisor/consultant

Dr. Sytkowski brings to Callisto considerable experience in oncology both as a practicing physician and through his industry experience in world-wide clinical development of cancer therapeutics. Dr. Sytkowski is currently Associate Professor of Medicine at Harvard University, and also serves as Callisto’s Clinical Trial Advisor and Medical Safety Monitor. Dr. Sytkowski brings to Callisto considerable experience with clinical development of cancer drugs from Phase I through Phase III, which he has gained through experience with a number of leading pharmaceutical and biotechnology companies. Dr. Sytkowski is also Director of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Sytkowski, who is board certified in internal medicine, received his M.D. degree from the Medical College of Wisconsin, followed by an internship and medical residency at the Peter Bent Brigham Hospital and a hematology/oncology fellowship at the Boston Children’s Hospital and the Dana Farber Cancer Institute, all at Harvard Medical School. Dr. Sytkowski has been an Associate Professor of Medicine at Harvard Medical School since 1986, and a Staff Physician at Beth Israel Deaconess Medical Center, Boston.

Kunwar Shailubhai, Ph.D., M.B.A.

Senior Vice President, Drug Discovery, Synergy Pharmaceuticals, Inc.

Kunwar Shailubhai, Ph.D., has served as Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc. since March 2004. From May 2003 until March 2004, Dr. Shailubhai served as Executive Vice President, Research and Development. From 2001 to April 2003, Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy Pharmaceuticals Inc where he was chiefly responsible for the preclinical development of Synergy’s GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000, he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his M.B.A. in 2001 from the University of Missouri, St. Louis.

Bernard F. Denoyer, M.B.A., C.P.A.

Vice President, Finance

Bernard F. Denoyer, CPA, has served as Vice President, Finance since January 2004. From July 2003 to December 2003, Mr. Denoyer served as an independent consultant to the company, providing interim CFO services. In addition, Mr. Denoyer provided interim CFO and other services to emerging technology companies, principally portfolio companies of Marsh & McLennan Capital, LLC, from October 2000 to December 2003. From October 1994 until September 2000, Mr. Denoyer served in various capacities with META Group, Inc., a public information technology research company, including Chief Financial Officer and Senior Vice President. From 1990 to 1993, Mr. Denoyer was vice President, Finance, of Environetics, Inc., a pharmaceutical diagnostic water test manufacturer. He also held senior financial management positions with Gartner Group, Bunker Ramo-Amphenol RF Division and GTE Sylvania consumer Electornics. Mr. Denoyer received his CPA with Ernst and Young in 1975, and an MBA in Finance, with honors, from Columbia Business School in 1973, and a B.A in Economics from Fairfield University in 1969.

Craig C. Talluto, Ph.D., ABD

Senior Director, Clinical Operations

Craig C. Talluto, Ph.D., ABD, has served as our Senior Director, Clinical Operations at Callisto since August 2006. Craig has over 10 years of broad pharmaceutical industry experience as an independent contractor working with clients in all phases of clinical trial development for both therapeutic and diagnostic product candidates. These clients included Amgen, Hoffman-La Roche and Kos Pharmaceuticals. Craig completed his residency and earned his Ph.D. in Physiology for Sport Science, with a supporting field in Clinical Immunology, from the University of Miami. Craig’s dissertation examined the effects of aerobic and resistance training on male respiratory physiology. He earned his Master of Science with a major in Exercise Physiology and his Bachelor of Science with a major in Marketing and Business Administration from the University of New Orleans.